BioAtla (BCAB) Operating Expenses (2020 - 2026)
BioAtla (BCAB) posted quarterly Operating Expenses of $9.3 million for Q1 2026, down 47.16% year-over-year from $17.6 million in Q1 2025, and down 17.3% quarter-over-quarter from $11.3 million in Q4 2025.
BioAtla (BCAB) Operating Expenses (2020 - 2026) Analysis & Trends
BioAtla's Operating Expenses history runs 7 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 47.16% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $53.0 million (down 32.14% YoY), while the FY2025 annual figure was $61.3 million, down 27.83% from the prior year.
- Operating Expenses for Q1 2026 stood at $9.3 million, down from $11.3 million in the prior quarter.
- The five-year high for Operating Expenses was $37.2 million in Q2 2023, with the low at $9.3 million in Q1 2026.
- The 5-year median for Operating Expenses is $24.3 million (2022), against an average of $23.1 million.
- The sharpest annual moves came in 2023 and 2026: Operating Expenses jumped 33.77% in 2023, then sank 47.16% in 2026.
- BioAtla's Operating Expenses stood at $28.6 million in 2022, then decreased by 0.08% to $28.5 million in 2023, then plunged by 43.08% to $16.2 million in 2024, then sank by 30.71% to $11.3 million in 2025, then retreated by 17.3% to $9.3 million in 2026.
- Business Quant data shows BCAB's Operating Expenses at $9.3 million in Q1 2026, $11.3 million in Q4 2025, and $13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | 6.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.27 Mn |
| Mar 31, 2026 | 9.31 Mn |
| Dec 31, 2025 | 11.26 Mn |
| Sep 30, 2025 | 13.79 Mn |
| Jun 30, 2025 | 18.65 Mn |
| Mar 31, 2025 | 17.61 Mn |
| Dec 31, 2024 | 16.24 Mn |
| Sep 30, 2024 | 22.27 Mn |
| Jun 30, 2024 | 21.97 Mn |
| Mar 31, 2024 | 24.46 Mn |
| Dec 31, 2023 | 28.54 Mn |
| Sep 30, 2023 | 35.02 Mn |
| Jun 30, 2023 | 37.20 Mn |
| Mar 31, 2023 | 28.93 Mn |
| Dec 31, 2022 | 28.56 Mn |
| Sep 30, 2022 | 26.18 Mn |
| Jun 30, 2022 | 29.06 Mn |
| Mar 31, 2022 | 24.35 Mn |
| Dec 31, 2021 | 23.49 Mn |
| Sep 30, 2021 | 23.70 Mn |